US Government to fund development of a 'universal flu vaccine'

NewsGuard 100/100 Score

The US government is to provide up to $400 million in funding to develop a “universal” flu vaccination. The project which will run for seven years is expected to generate a vaccine that offers more widespread protection and is longer-lasting than the current seasonal flu vaccine.

The influenza virusJuan Gaertner | Shutterstock

Why is a more comprehensive vaccine needed?

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded the Duke Human Vaccine Institute (DHVI) a total of three research contracts in order to develop a vaccine that is more comprehensive than it currently available.

It will be a huge project lasting several years and involving scientists from over 14 different research institutions and universities. The first year of research will receive an estimated $29.6 million in order to kick start the project. This represents the largest federal multi-contract award to back one program in the history of research at Duke.

Researchers involved in the project state that ideally the vaccine they would develop would cover people against flu for a lifetime. However, more realistically the vaccine would last for a period of five-to-ten years without needing a top-up. As research continues, the aim would be to gradually extend this period of cover.

The current method of vaccination is to construct yearly flu jabs that protect against the strains that scientists predict will be the most impactful during the coming flu season. This is usually a vaccine that protects for three or four strains temporarily.

Scientists are hoping to greatly improve on this by developing a vaccine that can target multiple weaknesses across a greater variety of strains.

The DHVI is a good choice for leading this kind of project. The institution is already recognized for its success in winning funding for HIV vaccine development, leading this field since 2005, in addition to conducting important work on other infectious diseases such as Tuberculosis, Malaria, Ebola, Cytomegalovirus and the Zika flavivirus.

A “universal” flu vaccine could save lives and reduce the burden on hospitals

Statistics show that influenza has a devastating impact each year, causing 300,000 to 500,000 people worldwide to lose their lives annually. Not only does the virus result in death, but it also puts huge strains on hospitals during each flu season, as around 5 million cases of severe infection bring significant numbers of infected people into hospitals around the world.

The development of a more thorough vaccine, that could protect against more than just a few strains that are predicted to impact each year, would potentially drastically reduce deaths and also reduce the need to rely on limited hospital resources.

Currently, the Centers for Disease Control and Protection (CDC) advise that everyone protects themselves wit an annual flu vaccine. However, in the US, less than half of adults and less than two-thirds of children get vaccinated each year.

A future without flu?

Being able to offer a long term vaccine could lead to more people being protected against flu than currently are using the seasonal jab method. Due to the vaccine’s longevity, even if less than 100% of the population decided to get vaccinated each year, as the year accumulated, the total percentage of those covered would exceed the current figures.

Scientists estimate that the universal flu vaccination could potentially provide a defense against flu that is up to 90% effective, whereas current vaccinations are only 40 to 60% effective.

This is significant for the future of battling the flu virus, with this level of effectiveness, coupled with the longevity of the vaccination, the developments expected to come out of the project at the DHVI are predicted to dramatically reduce death rates and the reliance on hospitals due to flu infection.

Sarah Moore

Written by

Sarah Moore

After studying Psychology and then Neuroscience, Sarah quickly found her enjoyment for researching and writing research papers; turning to a passion to connect ideas with people through writing.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Moore, Sarah. (2022, December 22). US Government to fund development of a 'universal flu vaccine'. News-Medical. Retrieved on May 10, 2024 from https://www.news-medical.net/news/20191001/US-Government-to-fund-development-of-a-universal-flu-vaccine.aspx.

  • MLA

    Moore, Sarah. "US Government to fund development of a 'universal flu vaccine'". News-Medical. 10 May 2024. <https://www.news-medical.net/news/20191001/US-Government-to-fund-development-of-a-universal-flu-vaccine.aspx>.

  • Chicago

    Moore, Sarah. "US Government to fund development of a 'universal flu vaccine'". News-Medical. https://www.news-medical.net/news/20191001/US-Government-to-fund-development-of-a-universal-flu-vaccine.aspx. (accessed May 10, 2024).

  • Harvard

    Moore, Sarah. 2022. US Government to fund development of a 'universal flu vaccine'. News-Medical, viewed 10 May 2024, https://www.news-medical.net/news/20191001/US-Government-to-fund-development-of-a-universal-flu-vaccine.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combination immunotherapy treatment enhances immune response for people with malignant gliomas